Skip to main content

Table 1 Baseline demographic and disease characteristics in all systemic JIA CTP patients

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

  GC (N = 2) MTX (N = 6) IL1 Inhibitor (N = 12) IL6 Inhibitor (N = 10) Total (N = 30) P-value
Age in yearsa 12.8 3.4 4.0 9.8 5.7 0.047
Female 50% 67% 92% 90% 83% 0.3
White 0% 83% 33% 80% 57% 0.03
Disease duration (days)a 121 38 31 55 42.5 0.2
Polyarthritis 0% 50% 67% 80% 63% 0.18
Number of active jointsa 1.0 4.5 5.0 5.5 4.0 0.28
ESR >3x ULN 100% 67% 91% 43% 73% 0.27
CRP >3x ULN 100% 83% 91% 40% 79% 0.28
Ferritin (ng/mL)a 12,874 1,394 1,062 627 783 0.09
CHAQ scorea 0.9 1.3 1.9 0.8 1.4 0.6
Pain score (0–10)a 3 6.5 6 7.5 6 0.6
Physician global assessment (0–10)a 4 7 5 5 5.5 0.12
Parent global assessment well-being (0–10)a 0 7 6 6 6 0.103
Initiated GC at baseline 100% 100% 42% 70% 67% 0.029
Initial GC dose (mg/kg)a 0.67 0.97 0.00 0.68 0.80 0.548
GC prior to baseline 50% 16.7% 8.3% 30% 20% 0.350
Initial dose of each CTP medication in mg/kg (IQR)a 0.67 (0.6–0.73) 0.487 (0.46–0.64) 2.93 (2–3.6)b 8.14 (8–12) Not Applicable  
  1. aMedian
  2. bAnakinra dose (anakinra was used as the initial IL-1i in all patients)